Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review
Muscle & Nerve · 2024
DOI: 10.1002/mus.28224 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Katie O'Brien und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Dietetics and Food, Monash University, Faculty of Medicine Nursing and Health Sciences, Melbourne, Australia. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Oligonucleotides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The nutritional implications of spinal muscular atrophy (SMA) are profound. Disease modifying therapies (DMT) have improved clinical outcomes. This review describes the impact of DMT on nutrition outcomes. A systematic search strategy was applied across seven databases until May 2023. Eligible studies measured nutrition outcomes in individuals with SMA on DMT (nusinersen, risdiplam or onasemnogene abeparvovec [OA]) compared to untreated comparators. Nutrition outcomes included anthropometry, feeding route, swallowing dysfunction, dietary intake, dietetic intervention, nutritional biochemistry, metabolism, gastrointestinal issues and energy expenditure. Articles retrieved were screened in duplicate, data were extracted and appraised systematically. Sixty three articles from 54 studies were included; 41% ( n = 22) investigated nusinersen in pediatric participants with SMA type 1. Anthropometry ( n = 18), feeding route ( n = 39), and swallowing dysfunction ( n = 18) were the most commonly reported outcomes. In combined pediatric and adult cohorts, BMI z‐score remained stable post nusinersen therapy. The proportion of children with SMA requiring enteral nutrition was stable post nusinersen therapy. Ability to thrive at age 1.5 years was higher in children treated in early infancy with OA compared to historical controls. Significant heterogeneity existed across study population characteristics and outcome measures. Nusinersen may prevent deterioration in some nutrition outcomes; and OA in early infancy may be associated with improved nutrition outcomes. Timing of DMT initiation is an important consideration for future nutrition research. Studies investigating nutrition as a primary outcome of DMT, using consistent outcome measures are required for nutritional management strategies for this cohort to be appropriately tailored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition, Dietetics and Food, Monash University, Faculty of Medicine Nursing and Health Sciences, Melbourne, Australia.
- Department of Nutrition and Food Services, Royal Children's Hospital, Melbourne, Australia.
- Department of Neurology, Royal Children's Hospital, Melbourne, Australia.
- Neurosciences Research, Murdoch Children's Research Institute, Melbourne, Australia.
- Department of Paediatrics, Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
- Molecular Therapies Research, Murdoch Children's Research Institute, Melbourne, Australia.
ORCID-Profile: Katie O'Brien, Natassja Billich
Zitieren
APA
O'Brien, K., Nguo, K., Yiu, E. M., Woodcock, I. R., Billich, N., & Davidson, Z. E. (2024). Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review. Muscle & Nerve. https://doi.org/10.1002/mus.28224
Vancouver
O'Brien K, Nguo K, Yiu EM, Woodcock IR, Billich N, Davidson ZE. Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review. Muscle & Nerve. 2024. doi:10.1002/mus.28224
BibTeX
@article{OBrien2024,
author = {O'Brien, Katie and Nguo, Kay and Yiu, Eppie M and Woodcock, Ian R and Billich, Natassja and Davidson, Zoe E},
title = {Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28224}
}
EUVIMED